Evidence map›Paper›PMID 38291479›Full record

SynthesisJournal of translational medicine2024

Circulating vitamin D level before initiating chemotherapy impacts on the time-to-outcome in metastatic colorectal cancer patients: systematic review and meta-analysis.

Alessandro Ottaiano, Maria Lucia Iacovino, Mariachiara Santorsola, Sergio Facchini, Domenico Iervolino, Francesco Perri, Guglielmo Nasti, Vincenzo Quagliariello, Nicola Maurea, Andrea Ronchi and 3 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Observational
  3. Oxidative Stress by HAntioxidants (Basel, Switzerland) · 2025
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Alessandro OttaianoIstituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", 80131, Naples, Italy.
Maria Lucia IacovinoDivision of Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138, Naples, Italy.ORCID 0000-0001-9957-6170
Mariachiara SantorsolaIstituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", 80131, Naples, Italy.
Sergio FacchiniDivision of Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138, Naples, Italy.ORCID 0000-0003-0684-6683
Domenico IervolinoIstituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", 80131, Naples, Italy.
Francesco PerriIstituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", 80131, Naples, Italy.
Guglielmo NastiIstituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", 80131, Naples, Italy.
Vincenzo QuagliarielloDivision of Cardiology, IRCCS "G. Pascale", 80131, Naples, Italy.
Nicola MaureaDivision of Cardiology, IRCCS "G. Pascale", 80131, Naples, Italy.
Andrea RonchiPathology Unit, Department of Mental Health and Physic and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Bianca Arianna FacchiniDivision of Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138, Naples, Italy.
Alessia BignucoloIntegrative Medicine Research Group (IMRG), Noceto, 43015, Parma, Italy.
Massimiliano BerrettaIntegrative Medicine Research Group (IMRG), Noceto, 43015, Parma, Italy. mberretta@unime.it.ORCID 0000-0002-9837-9148
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVitamin D (VD) is implicated in various health conditions, including colorectal cancer (CRC). To investigate potential relationships between pre-chemotherapy VD levels and the time-to-outcome in metastatic CRC patients, we conducted a systematic review and meta-analysis.

methodsFollowing the PRISMA 2020 guidelines, we performed thorough searches in PubMed/MEDLINE and Scopus/ELSEVIER databases (covering the years 2002 to 2022). Inclusion criteria mandated studies to report on individuals aged 18 years and above with histologically confirmed stage IV CRC. Additionally, studies needed to provide data on VD levels before chemotherapy, along with hazard ratios (HR) and 95% confidence intervals (CIs) for overall survival (OS) and/or progression-free survival (PFS). Five articles were identified with the aim of establishing a combined risk estimate for death and progression based on pre-chemotherapy VD levels. Heterogeneity among studies and publication bias were evaluated using Tau

resultsAlthough no significant heterogeneity was observed in time-to-outcome among the selected studies, variations in technical assessments and serum VD concentration measurements were noted. The pooled analysis, involving 1712 patients for OS and 1264 patients for PFS, revealed a 47% increased risk of death (HR: 1.47, 95% CI: 1.21-1.79) and a 38% increased risk of progression (HR: 1.38, 95% CI: 1.13-1.70) for patients with lower VD levels, as indicated by fixed-effects models.

conclusionsOur results emphasize the adverse effects of low VD concentration on the time-to-outcome in metastatic CRC patients. This underscores the importance of investigating VD supplementation as an innovative approach in this clinical setting to enhance patient outcomes.

Indexed as

Colonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsHumansProportional Hazards ModelsVitamin DVitamin DMeta-analysisMetastatic colorectal cancerOverall survivalPrognosisProgression-free survivalVitamin D

Identifiers

PMID38291479
PMCPMC10826188
OpenAlexW4391360784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.